pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
Argenx clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Argenx projects
8 ClinicalTrials.gov programs sponsored by Argenx.
Argenx has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ARGX-113-2302
argenx
Antibody-Mediated Rejection
1 trial -
ARGX-113-2317
argenx
Systemic Sclerosis
1 trial -
ARGX-117, ARGX-113
argenx
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
1 trial -
ARGX-117-2003
argenx
Multifocal Motor Neuropathy
1 trial -
ARGX-117-2301
argenx
Myositis, Dermatomyositis
1 trial -
ARGX-119-2302
argenx
congenital neuromuscular disorders
1 trial -
ARGX-119-2303
argenx
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
Efgartigimod, ARGX-113
argenx
Chronic Inflammatory Demyelinating Polyneuropathy
1 trial
Frequently asked questions
How many clinical projects does Argenx have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.